Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Axovant failed. Now what? A collection of takes hot and cold

  • Damian Garde
  • Adam Feuerstein

By Damian Garde and Adam Feuerstein Sept. 26, 2017

Reprints
Vivek Ramaswamy
Roivant founder Vivek Ramaswamy took a hit, but investors still signaled belief in his model. Chantal Heijnen for STAT

It finally happened. Biotech’s most anticipated data readout of the year, an Axovant Sciences trial in Alzheimer’s disease, came back, and it came back negative.

Now what?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Experts weigh in on potential health hazards posed by…
Experts weigh in on potential health hazards posed by chemicals in Ohio train derailment
There’s no autism epidemic. But there is an autism…
There’s no autism epidemic. But there is an autism diagnosis epidemic
Our child received a devastating diagnosis before she was…
Our child received a devastating diagnosis before she was born. We decided to protect her
Patient groups balk at former AstraZeneca official negotiating U.K.-India…
Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
Pharmalittle: FDA official wants to use accelerated approval for…
Pharmalittle: FDA official wants to use accelerated approval for gene therapies; pharma asks Biden for tax…

Recommended Stories